Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABA(A) potentiating activity for use in dementia

BACKGROUND: Synaptic dysfunction is a key event in pathogenesis of neurodegenerative diseases such as Alzheimer’s disease (AD) where synapse loss pathologically correlates with cognitive decline and dementia. Although evidence suggests that aberrant protein production and aggregation are the causati...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Neurosci
Hlavní autoři: Luo, Jia, Lee, Sue H., VandeVrede, Lawren, Qin, Zhihui, Piyankarage, Sujeewa, Tavassoli, Ehsan, Asghodom, Rezene T., Aissa, Manel Ben, Fà, Mauro, Arancio, Ottavio, Yue, Lan, Pepperberg, David R., Thatcher, Gregory R. J.
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2015
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4612403/
https://ncbi.nlm.nih.gov/pubmed/26480871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12868-015-0208-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky